AI assistant
Cocrystal Pharma, Inc. — Director's Dealing 2025
Oct 30, 2025
35066_dirs_2025-10-30_07b89b6c-3a52-4bab-9ee7-9988e0112812.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2025-10-28
Reporting Person: PFENNIGER RICHARD C JR (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-28 | Common Stock | A | 20000 | — | Acquired | 31400 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-10-28 | Warrants | $1.24 | A | 40000 | Acquired | 2028-01-28 | Common Stock (40000) | Direct |
Footnotes
F1: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.
F2: Includes shares of common stock issuable upon vesting of restricted stock units.